The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

As vacation prices continue to rise, it's getting harder to lock down a cheap all-inclusive stay – but it's certainly not impossible. Beachy hot spots like Curaçao or St. Lucia may be out of ...